ArticleRevista do Colegio Brasileiro de Cirurgioes2024
Assessment of quality of life using the EORTC 30 protocol in patients with soft tissue sarcoma undergoing surgical treatment.
Article in Revista do Colegio Brasileiro de Cirurgioes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the quality of life among patients with Soft Tissue Sarcomas treated at the Evangelic Mackenzie Hospital (HUEM) from 2018 to 2024 and undergoing surgical treatment. MATERIAL AND
methodsdescriptive and cross-sectional analysis of 23 patients with soft tissue neoplasia who underwent surgery and whether they underwent neoadjuvant or adjuvant clinical treatments. Epidemiological, clinical, and pathological data were considered. The EORTC 30 protocol was the instrument used for assessing the patients' quality of life.
resultsthe main cases were located at extremity in females. Mean age at diagnosis was 47 years. All patients were symptomatic at diagnosis, with pain and a palpable mass being the most prevalent symptom and clinical sign, respectively. The mean time from the onset of symptoms to the date of diagnosis was 9 months. The mean tumor size was 11.68cm. Considering the functional scale, the items physical functioning, role performance and social function were the most affected in the assessment of quality of life. Fatigue and loss of appetite were the most common sign and symptom, respectively. A global measure of quality of life achieved high rates when 50% of patients rated as excellent.
conclusionContinuous and multidisciplinary oncological care provided to the patient allows for better symptom control, resulting in higher quality of life, which positively impacts the patient's adherence to treatment, their progression, and possibly their survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.